The Australian medical community is buzzing with the emergence of retatrutide, a novel dual GIP and GLP-1 receptor agonist showing remarkable results in clinical trials for addressing obesity. This medication https://bookmarkbooth.com/story21786096/retatrutide-australia-a-emerging-prospect-for-obesity-treatment